Mariner LLC decreased its holdings in shares of Waters Co. (NYSE:WAT - Free Report) by 10.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 6,999 shares of the medical instruments supplier's stock after selling 859 shares during the quarter. Mariner LLC's holdings in Waters were worth $2,596,000 as of its most recent SEC filing.
Several other institutional investors have also bought and sold shares of the business. Wealthfront Advisers LLC raised its position in shares of Waters by 106,144.4% during the 4th quarter. Wealthfront Advisers LLC now owns 3,087,461 shares of the medical instruments supplier's stock valued at $1,145,386,000 after buying an additional 3,084,555 shares in the last quarter. Norges Bank bought a new stake in shares of Waters in the 4th quarter valued at approximately $284,415,000. Madison Investment Advisors LLC bought a new stake in shares of Waters in the 4th quarter valued at approximately $104,645,000. Principal Financial Group Inc. boosted its holdings in shares of Waters by 70.7% in the 3rd quarter. Principal Financial Group Inc. now owns 656,019 shares of the medical instruments supplier's stock worth $236,095,000 after purchasing an additional 271,804 shares during the period. Finally, Alliancebernstein L.P. increased its position in shares of Waters by 8.7% during the 4th quarter. Alliancebernstein L.P. now owns 2,654,002 shares of the medical instruments supplier's stock valued at $984,582,000 after purchasing an additional 212,364 shares during the last quarter. Institutional investors own 94.01% of the company's stock.
Wall Street Analyst Weigh In
Several research analysts have commented on WAT shares. Barclays dropped their price objective on shares of Waters from $400.00 to $350.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. StockNews.com downgraded shares of Waters from a "buy" rating to a "hold" rating in a report on Tuesday, February 25th. Bank of America reduced their price objective on shares of Waters from $430.00 to $410.00 and set a "neutral" rating on the stock in a research report on Thursday, February 13th. Wells Fargo & Company boosted their target price on Waters from $415.00 to $420.00 and gave the company an "overweight" rating in a research report on Thursday, February 13th. Finally, UBS Group increased their price target on Waters from $405.00 to $410.00 and gave the stock a "neutral" rating in a report on Thursday, February 13th. Ten equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus price target of $392.13.
Get Our Latest Research Report on Waters
Waters Stock Up 4.8 %
Shares of Waters stock opened at $331.27 on Wednesday. The company has a debt-to-equity ratio of 1.14, a current ratio of 0.94 and a quick ratio of 0.65. The stock has a market cap of $19.71 billion, a price-to-earnings ratio of 30.93, a PEG ratio of 3.79 and a beta of 1.04. The firm's 50-day moving average is $358.01 and its two-hundred day moving average is $370.81. Waters Co. has a 1 year low of $279.24 and a 1 year high of $423.56.
Waters (NYSE:WAT - Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $4.02 by $0.08. Waters had a net margin of 21.56% and a return on equity of 46.31%. As a group, research analysts expect that Waters Co. will post 12.86 earnings per share for the current fiscal year.
Waters Company Profile
(
Free Report)
Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments: Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Waters, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waters wasn't on the list.
While Waters currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
